Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth

Stock Track04-09

BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.

The movement appears driven by the company's promising drug candidates, particularly KJ017 which is China's most advanced domestic recombinant hyaluronidase with NDA approval and expected launch in the first half of the year. The company's revenue grew significantly from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization.

Additionally, BAO PHARMA-B maintains a strong financial position with cash and equivalents of RMB1.2416 billion against manageable debt, while its pipeline includes multiple breakthrough therapy-designated candidates addressing significant market opportunities in subcutaneous drug delivery, kidney transplantation, and assisted reproduction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174331901?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 13:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174331901","market":"sg","top_or_hot":-1,"title":"Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth","media":"Stock Track","content":"<p>BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.</p><p>The movement appears driven by the company's promising drug candidates, particularly KJ017 which is China's most advanced domestic recombinant hyaluronidase with NDA approval and expected launch in the first half of the year. The company's revenue grew significantly from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization.</p><p>Additionally, BAO PHARMA-B maintains a strong financial position with cash and equivalents of RMB1.2416 billion against manageable debt, while its pipeline includes multiple breakthrough therapy-designated candidates addressing significant market opportunities in subcutaneous drug delivery, kidney transplantation, and assisted reproduction.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-09 13:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.</p><p>The movement appears driven by the company's promising drug candidates, particularly KJ017 which is China's most advanced domestic recombinant hyaluronidase with NDA approval and expected launch in the first half of the year. The company's revenue grew significantly from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization.</p><p>Additionally, BAO PHARMA-B maintains a strong financial position with cash and equivalents of RMB1.2416 billion against manageable debt, while its pipeline includes multiple breakthrough therapy-designated candidates addressing significant market opportunities in subcutaneous drug delivery, kidney transplantation, and assisted reproduction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1174331901","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174331901","pubTimestamp":1775714297,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.The movement appears...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"个股赛道|宝药业-B盘中大涨5.02%管线前景强劲及营收增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.The movement appears driven by the company's promising drug candidates, particularly KJ017 which is China's most advanced domestic recombinant hyaluronidase with NDA approval and expected launch in the first half of the year. The company's revenue grew significantly from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization.Additionally, BAO PHARMA-B maintains a strong financial position with cash and equivalents of RMB1.2416 billion against manageable debt, while its pipeline includes multiple breakthrough therapy-designated candidates addressing significant market opportunities in subcutaneous drug delivery, kidney transplantation, and assisted reproduction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174331901","isCrawlerRequest":true}